title: [A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel].
abstract: Docetaxel is an excellent agent with a high antitumor effect for advanced/recurrent head and neck cancer. A 67-year-old male with advanced hypopharyngeal cancer (T3N2bM1: Stage IV) underwent two courses of superselective intra-arterial infusion of docetaxel and intravenous administration of CDDP and 5-FU. Using a coaxial technique, a microcatheter was placed in the feeding artery. Using imaging techniques docetaxel (60 mg/body and 30 mg/body) was infused into the vessels. During chemotherapy the patient received concomitant radiotherapy (50 Gy). MRI after chemoradiation showed a complete response for the primary tumor and a partial response for the neck metastasis. Grade 4 leukopenia and neutropenia and grade 3 pharyngitis/esophagitis were observed during chemoradiotherapy, but these adverse effects abated immediately and were not critical. We conclude that this superselective intra-arterial infusion of docetaxel will be useful and safe for head and neck cancer.
authors.affiliation: Dept. of Otorhinolaryngology, Kawasaki Medical School.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Akisada
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Harada
authors.forename: Takuji
authors.initials: T
authors.lastname: Takemoto
authors.forename: Kazuyasu
authors.initials: K
authors.lastname: Fukuda
authors.forename: Norimasa
authors.initials: N
authors.lastname: Morita
authors.forename: Teruhito
authors.initials: T
authors.lastname: Aihara
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Kajihara
authors.forename: Shigeki
authors.initials: S
authors.lastname: Imai
authors.forename: Masayuki
authors.initials: M
authors.lastname: Gyoten
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Imajo
authors.forename: Junichi
authors.initials: J
authors.lastname: Hiratsuka
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D000077143:Docetaxel; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D007261:Infusions, Intra-Arterial; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil